NHS England Expands Access to Weight-Loss Drug for Cardiovascular Protection
In a landmark move, NHS England is set to offer weight-loss drugs to approximately 1.2 million people to reduce their risk of heart attacks and strokes. This initiative targets individuals who are not obese but overweight and at high risk of serious cardiovascular events, making them eligible for weekly injections of semaglutide, commonly known under brand names such as Wegovy and Ozempic.
New Eligibility Criteria Based on Clinical Evidence
The decision follows draft guidance from the National Institute for Health and Care Excellence (Nice), which recommends offering semaglutide to people with a body mass index (BMI) of 27 or above who have previously experienced a heart attack, stroke, or serious circulation issues in their legs. This expansion builds on existing NHS provisions where semaglutide is already available for some individuals with obesity and for treating type 2 diabetes.
Clinical trials have demonstrated that semaglutide significantly reduces the risk of heart attack, stroke, or cardiovascular death. Notably, these benefits were observed even before substantial weight loss occurred, suggesting the drug acts directly on the heart and blood vessels, beyond its weight-reduction effects. A major study led by University College London (UCL), published in the Lancet, found that semaglutide cuts cardiovascular risk regardless of the amount of weight lost, indicating broader therapeutic advantages.
Enhanced Treatment Approach for High-Risk Patients
The weekly injections will be provided as an additional treatment alongside existing medications like statins, complemented by a reduced-calorie diet and increased physical activity. This integrated approach aims to offer an extra layer of protection for those at heightened risk of recurrent cardiovascular events. Helen Knight, director of medicines evaluation at Nice, described the evidence from the UCL study as "compelling," highlighting that patients on semaglutide were "significantly less likely" to experience another heart attack or stroke.
NHS England officials anticipate that eligible individuals will be able to access semaglutide within months, pending final approval of the draft guidance. Helen Williams, NHS England's clinical director for cardiovascular disease prevention, emphasized that this treatment could be "life-changing" for over a million high-risk patients, helping prevent thousands of future major cardiovascular events and promoting longer, healthier lives.
Widespread Support from Health Experts and Officials
Health Minister Sharon Hodgson hailed weight-loss drugs as a "gamechanger" and a potential "lifesaver" for those at risk of heart attacks and strokes. Dr. Sonya Babu-Narayan, clinical director of the British Heart Foundation, noted that semaglutide offers benefits "beyond reducing the number on the scales," positioning it as an important medicine for cardiovascular prevention. Professor Naveed Sattar from the University of Glasgow praised the move, citing high-quality trial evidence that supports both cardiovascular risk reduction and meaningful weight loss, improving patients' quality of life.
However, Professor Riyaz Patel of UCL raised concerns about the NHS's capacity to deliver the drug to such a large population, calling it a "really exciting development" that provides a powerful new tool against cardiovascular disease. This expansion reflects a strategic effort to balance clinical effectiveness with efficient use of NHS resources, aiming to address the growing burden of cardiovascular conditions in England.
